Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai, Junzo Hamanishi, Kaoru Abiko, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 10, pp. 2329-2334
Open Access | Times Cited: 344

Showing 1-25 of 344 citing articles:

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 3, pp. 197-218
Closed Access | Times Cited: 2622
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 3, pp. 151-167
Closed Access | Times Cited: 1426
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang, Jie Wang, Xiangying Deng, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 1158
Roles of IFN-γ in tumor progression and regression: a review
Dragica Jorgovanović, Mengjia Song, Liping Wang, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 849
In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang, Jinqiang Wang, Xudong Zhang, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 429
Open Access | Times Cited: 514
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha, Robert L. Martuza, Samuel D. Rabkin
Cancer Cell (2017) Vol. 32, Iss. 2, pp. 253-267.e5
Open Access | Times Cited: 501
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stéphane Champiat, Roberto Ferrara, Christophe Massard, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 12, pp. 748-762
Closed Access | Times Cited: 331
Mechanisms regulating T-cell infiltration and activity in solid tumors
Evripidis Lanitis, Denarda Dangaj, Melita Irving, et al.
Annals of Oncology (2017) Vol. 28, pp. xii18-xii32
Open Access | Times Cited: 326
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Florida Voli, Emanuele Valli, Luigi Lerra, et al.
Cancer Research (2020) Vol. 80, Iss. 19, pp. 4129-4144
Open Access | Times Cited: 293
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 22, pp. 5710-5723
Open Access | Times Cited: 290
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
Xiaohui Zhang, Yuanyuan Zeng, Qiu‐Xia Qu, et al.
International Journal of Clinical Oncology (2017) Vol. 22, Iss. 6, pp. 1026-1033
Closed Access | Times Cited: 272
Cytokines in immunogenic cell death: Applications for cancer immunotherapy
Anne Showalter, Arati Limaye, Jeremiah L. Oyer, et al.
Cytokine (2017) Vol. 97, pp. 123-132
Open Access | Times Cited: 270
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Sarah Derks, Xiaoyun Liao, Anna Maria Chiaravalli, et al.
Oncotarget (2016) Vol. 7, Iss. 22, pp. 32925-32932
Open Access | Times Cited: 264
The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1422-1437
Open Access | Times Cited: 252
Regulation of PD-L1 Expression by NF-κB in Cancer
Fabrizio Antonangeli, Ambra Natalini, Marina Chiara Garassino, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 250
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Hannah Yang, Won Suk Lee, So Jung Kong, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 10, pp. 4350-4364
Open Access | Times Cited: 232
The role of cytokines in the regulation of NK cells in the tumor environment
Gordana Konjević, Ana Vuletić, Katarina Mirjačić Martinović, et al.
Cytokine (2019) Vol. 117, pp. 30-40
Closed Access | Times Cited: 225
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy
Xiaodong Wang, Xiaohui Yang, Chang Zhang, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 12, pp. 6640-6650
Open Access | Times Cited: 196
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Chunwan Lu, Priscilla S. Redd, Jeffrey R. Lee, et al.
OncoImmunology (2016) Vol. 5, Iss. 12, pp. e1247135-e1247135
Open Access | Times Cited: 193
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 8, pp. 2037-2046
Open Access | Times Cited: 192
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Jinfang Zhang, Fabin Dang, Junming Ren, et al.
Trends in Biochemical Sciences (2018) Vol. 43, Iss. 12, pp. 1014-1032
Open Access | Times Cited: 183
IFN‐γ‐mediated inhibition of lung cancer correlates with PD‐L1 expression and is regulated by PI3K‐AKT signaling
Yi Gao, Jianjian Yang, Yixin Cai, et al.
International Journal of Cancer (2018) Vol. 143, Iss. 4, pp. 931-943
Open Access | Times Cited: 182
Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
Shabnam Shalapour, Michael Karin
Immunity (2019) Vol. 51, Iss. 1, pp. 15-26
Open Access | Times Cited: 175
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Ricardo Costa, Brian J. Czerniecki
npj Breast Cancer (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 140
Page 1 - Next Page

Scroll to top